AAPS PharmSciTech

, 20:250 | Cite as

Pharmaceutical Topical Delivery of Poorly Soluble Polyphenols: Potential Role in Prevention and Treatment of Melanoma

  • Gayathri Heenatigala Palliyage
  • Somnath Singh
  • Charles R. AshbyJr
  • Amit K. Tiwari
  • Harsh ChauhanEmail author
Review Article Theme: Advances in Topical Delivery of Drugs
Part of the following topical collections:
  1. Theme: Advances in Topical Delivery of Drugs


Melanoma is regarded as the fifth and sixth most common cancer in men and women, respectively, and it is estimated that one person dies from melanoma every hour in the USA. Unfortunately, the treatment of melanoma is difficult because of its aggressive metastasis and resistance to treatment. The treatment of melanoma continues to be a challenging issue due to the limitations of available treatments such as a low response rate, severe adverse reactions, and significant toxicity. Natural polyphenols have attracted considerable attention from the scientific community due to their chemopreventive and chemotherapeutic efficacy. It has been suggested that poorly soluble polyphenols such as curcumin, resveratrol, quercetin, coumarin, and epigallocatechin-3-gallate may have significant benefits in the treatment of melanoma due to their antioxidant, anti-inflammatory, antiproliferative, and chemoprotective efficacies. The major obstacles for the use of polyphenolic compounds are low stability and poor bioavailability. Numerous nanoformulations, including solid lipid nanoparticles, polymeric nanoparticles, micelles, and liposomes, have been formulated to enhance the bioavailability and stability, as well as the therapeutic efficacy of polyphenols. This review will provide an overview of poorly soluble polyphenols that have been reported to have antimetastatic efficacy in melanomas.


melanoma polyphenol topical transdermal delivery poor solubility curcumin resveratrol quercetin chemoprevention 



  1. 1.
    Abolmaali SS, Tamaddon AM, Salmanpour M, Mohammadi S, Dinarvand R. Block ionomer micellar nanoparticles from double hydrophilic copolymers, classifications and promises for delivery of cancer chemotherapeutics. Eur J Pharm Sci. 2017;104:393–405.PubMedGoogle Scholar
  2. 2.
    Aggarwal, Surh YJ. In: Shishodia S, editor. In the molecular targets and therapeutic uses of curcumin in health and disease (series volume 595 ed.). New York: Springer; 2007. p. 1–75.Google Scholar
  3. 3.
    Akhtar N. Vesicles: a recently developed novel carrier for enhanced topical drug delivery. Curr Drug Deliv. 2014;11(1):87–97.PubMedGoogle Scholar
  4. 4.
    Alam S, Panda JJ, Chauhan VS. Novel dipeptide nanoparticles for effective curcumin delivery. Int J Nanomedicine. 2012;7:4207–22.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Alexander A, Dwivedi S, Ajazuddin GTK, Saraf S, Saraf S, Tripathi DK. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release. 2012;164(1):26–40. Scholar
  6. 6.
    American Academy of Dermatology Association. 2018. Skin cancer. Retrieved 03/10, 2018, from
  7. 7.
    American Cancer Society. 2018. Key statistics for melanoma skin cancer. Retrieved 03/10, 2018, from
  8. 8.
    Anand P, Kunnumakkara A, Newman R, Aggarwal B. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.PubMedGoogle Scholar
  9. 9.
    Androutsopoulos VP, Fragiadaki I, Tosca A. Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4′-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp Dermatol. 2015;24(8):632–4.PubMedGoogle Scholar
  10. 10.
    Androutsopoulos VP, Fragiadaki I, Spandidos DA, Tosca A. The resveratrol analogue, 3,4,5,4′-trans-tetramethoxystilbene, inhibits the growth of A375 melanoma cells through multiple anticancer modes of action. Int J Oncol. 2016;49(4):1305–14.PubMedGoogle Scholar
  11. 11.
    Ansari K, Vavia P, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech. 2011;12(1):279–86.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release. 2014;190:15–28.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm. 2008;364(2):227–36.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Asensi M, Ortega A, Mena S, Feddi F, Estrela J. Natural polyphenols in cancer therapy. Crit Rev Clin Lab Sci. 2011;48(5–6):197–216. Scholar
  15. 15.
    Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. 2009. Scholar
  16. 16.
    Barry B. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14(2):101–14. Scholar
  17. 17.
    Barui S, Saha S, Yakati V, Chaudhuri A. Systemic codelivery of a homoserine derived ceramide analogue and curcumin to tumor vasculature inhibits mouse tumor growth. Mol Pharm. 2015;13(2):404–19.Google Scholar
  18. 18.
    Barui S, Saha S, Yakati V, Chaudhuri A. Systemic Codelivery of a Homoserine Derived Ceramide Analogue and Curcumin to Tumor Vasculature Inhibits Mouse Tumor Growth. Mol Pharm. 2016;13(2):404–19.PubMedGoogle Scholar
  19. 19.
    Bellocq N, Pun S, Jensen G, Davis M. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem. 2003;14(6):1122–32.PubMedGoogle Scholar
  20. 20.
    Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica. 2013;2013.Google Scholar
  21. 21.
    Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007;109(6):2293.PubMedGoogle Scholar
  22. 22.
    Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park, NY). 2009;23(6):488–96.Google Scholar
  23. 23.
    Bhattacharya S, Darjatmoko S, Polans A. Resveratrol modulates the malignant properties of cutaneous melanoma via changes in the activation and attenuation of the anti-apoptotic proto-oncogenic protein Akt/PKB. Melanoma Res. 2011;21(3):180–7.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Bhattacharyya SS, Paul S, De A, Das D, Samadder A, Boujedaini N, et al. Poly (lactide-co-glycolide) acid nanoencapsulation of a synthetic coumarin: cytotoxicity and bio-distribution in mice, in cancer cell line and interaction with calf thymus DNA as target. Toxicol Appl Pharmacol. 2011;253(3):270–81. Scholar
  25. 25.
    Bishayee K, Khuda-Bukhsh A, Huh S. PLGA-loaded gold-nanoparticles precipitated with quercetin downregulate HDAC-akt activities controlling proliferation and activate p53-ROS crosstalk to induce apoptosis in hepatocarcinoma cells. Mol Cell. 2015;38(6):518.Google Scholar
  26. 26.
    Boesch-Saadatmandi C, Loboda A, Wagner AE, Stachurska A, Jozkowicz A, Dulak J, et al. Effect of quercetin and its metabolites isorhamnetin and quercetin-3-glucuronide on inflammatory gene expression: role of miR-155. J Nutr Biochem. 2011;22(3):293–9.PubMedGoogle Scholar
  27. 27.
    Boesch-Saadatmandi C, Wagner AE, Wolffram S, Rimbach G. Effect of quercetin on inflammatory gene expression in mice liver in vivo—role of redox factor 1, miRNA-122 and miRNA-125b. Pharmacol Res. 2012;65(5):523–30.PubMedGoogle Scholar
  28. 28.
    Bommarito AA. In JoAl’s Products LLC (Ed.), Topical turmeric skin care products (US7763289B2 ed.). US; 2005.Google Scholar
  29. 29.
    Bouska A, Lushnikova T, Plaza S, Eischen CM. Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol. 2008;28(15):4862–74.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Bray S, Schorl C, Hall P. The challenge of p53: linking biochemistry, biology, and patient management. Stem Cells. 1998;16(4):248–60.PubMedGoogle Scholar
  31. 31.
    Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006;13(3):175–87.PubMedGoogle Scholar
  32. 32.
    Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010;10(5):342.PubMedGoogle Scholar
  33. 33.
    Bush JA, Cheung KJ, Li G. Curcumin induces apoptosis in human melanoma cells through a fas receptor/caspase-8 pathway independent of p53. US Natl Library Med. 2001;271(2):305–14.Google Scholar
  34. 34.
    Caddeo C, Nacher A, Vassallo A, Armentano MF, Pons R, Fernàndez-Busquets X, et al. Effect of quercetin and resveratrol co-incorporated in liposomes against inflammatory/oxidative response associated with skin cancer. Int J Pharm. 2016;513(1–2):153–63.PubMedGoogle Scholar
  35. 35.
    Cao H. A mechanistic study on the anti-melanoma action of quercetin (Doctoral dissertation, Hong Kong Baptist University.). 2015.Google Scholar
  36. 36.
    Cao H, Cheng C, Su T, Fu X, Guo H, Li T, et al. Quercetin inhibits HGF/c-met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer. 2015;14:103.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Carletto B, Berton J, Ferreira TN, Dalmolin LF, Paludo KS, Mainardes RM, et al. Resveratrol-loaded nanocapsules inhibit murine melanoma tumor growth. Colloids Surf B: Biointerfaces. 2016;144:65–72.PubMedGoogle Scholar
  38. 38.
    Cevc G, Gebauer D, Stieber J, Schätzlein A, Blume G. Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta. 1998;1368(2):201–15.PubMedGoogle Scholar
  39. 39.
    Chang A, Karnell L, Menck H. The national cancer data base report on cutaneous and noncutaneous melanoma. 1998;83(8):1664–78.Google Scholar
  40. 40.
    Chen J, Li L, Su J, Li B, Chen T, Wong Y. Synergistic apoptosis-inducing effects on A375 human melanoma cells of natural borneol and curcumin. PLoS One. 2014;9(6):e101277.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Chen Y, Wu Q, Zhang Z, Yuan L, Liu X, Zhou L. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules (Basel, Switzerland). 2012;17(5):5972–87.Google Scholar
  42. 42.
    Coleman W. In: Coleman W, Tsongalis GJ, editors. Diagnostic molecular pathology. London: Elsevier Academic Press; 2016.Google Scholar
  43. 43.
    Cosco D, Paolino D, Maiuolo J, Marzio LD, Carafa M, Ventura CA, et al. Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery. Int J Pharm. 2015;489(1–2):1–10.PubMedGoogle Scholar
  44. 44.
    Dandamudi S, Campbell RB. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim Biophys Acta Biomembr. 2007;1768(3):427–38.Google Scholar
  45. 45.
    Davies MA. The role of the PI3K–AKT pathway in melanoma. Cancer J. 2012;18(2):142–7.PubMedGoogle Scholar
  46. 46.
    De Unamuno B, Palanca S, Botella R. Update on melanoma epigenetics. Curr Opin Oncol. 2015;27(5):420–6.PubMedGoogle Scholar
  47. 47.
    Deepthi CHN, Kumar V, Babu R, Darshini U. Role of tumor suppressor protein p53 in apoptosis and cancer therapy. J Cancer Sci Ther. 2011;03(06).Google Scholar
  48. 48.
    Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol. 2010;27(7):247–59.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Deshmukh AS, Chauhan PN, Noolvi MN, Chaturvedi K, Ganguly K, Shukla SS, et al. Polymeric micelles: basic research to clinical practice. Int J Pharm. 2017;532(1):249–68.PubMedGoogle Scholar
  50. 50.
    Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res. 2002;62(24):7335–42.PubMedGoogle Scholar
  51. 51.
    Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–9.PubMedGoogle Scholar
  52. 52.
    Diccianni MB, Chilcote RR, Yu AL. The genes of chromosomes 9p21 (p16, p15, ARF, MTAP) in pediatric acute leukemia: inactivation and exploitation for tumor-targeted therapeutics. Trends Cancer. 2007;2:135–49.Google Scholar
  53. 53.
    Ding B, Yu J, Yu R, Mendez L, Shaknovich R, Zhang Y, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2007;111(3):1515–23.PubMedGoogle Scholar
  54. 54.
    Donnelly RF, Singh TRR, Garland MJ, Migalska K, Majithiya R, Mccrudden CM, et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv Funct Mater. 2012;22(23):4879–90.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Dragicevic N, Maibach H. Nanocarriers. Percutaneous penetration enhancers chemical methods in penetration enhancement. 1st ed. Berlin: Springer; 2016. p. 384.Google Scholar
  56. 56.
    Drexler I, Antunes E, Schmitz M, Wölfel T, Huber C, Erfle V, et al. Modified vaccinia virus ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res. 1999;59(19):4955.PubMedGoogle Scholar
  57. 57.
    Dubs-Poterszman M, Tocque B, Wasylyk B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene. 1995;11(11):2445–9.PubMedGoogle Scholar
  58. 58.
    Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem Biophys Res Commun. 2011;414(3):551–6.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Ernest U, Chen HY, Xu MJ, Taghipour YD, Asad MHHB, Rahimi R, et al. Anti-cancerous potential of polyphenol-loaded polymeric nanotherapeutics. Molecules. 2018;23(11):E2787. Scholar
  60. 60.
    Eskandarpour M. Molecular genetics of cutaneous malignant melanoma. Unpublished doctoral dissertation, Karolinka institute, Repoprint AB Stockholm. 2007.Google Scholar
  61. 61.
    Fagotto F, Glück U, Gumbiner BM. Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of β-catenin. Curr Biol. 1998;8(4):181–90. Scholar
  62. 62.
    Faiao-Flores F, Quincoces Suarez J, Fruet A, Maria-Engler S, Pardi P, Maria D. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression. PLoS One. 2015;10(3):e0118702.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Fang J, Hung C, Hwang T, Huang Y. Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J Drug Target. 2005;13(1):19–27.PubMedGoogle Scholar
  64. 64.
    Fang Y, Bradley M, Cook K, Herrick E, Nicholl M. A potential role for resveratrol as a radiation sensitizer for melanoma treatment. J Surg Res. 2013;183(2):645–53.PubMedGoogle Scholar
  65. 65.
    Farrar MD, Nicolaou A, Clarke KA, Mason S, Massey KA, Dew TP, et al. A randomized controlled trial of green tea catechins in protection against ultraviolet radiation-induced cutaneous inflammation. Am J Clin Nutr. 2015;102(3):608–15.PubMedPubMedCentralGoogle Scholar
  66. 66.
    FDA Guidance for Industry. Nonprescription sunscreen drug products—safety and effectiveness data. 2016. [Accessed on 19 July 2018].
  67. 67.
    Feng T, Wei Y, Lee RJ, Zhao L. Liposomal curcumin and its application in cancer. Int J Nanomedicine. 2017;12:6027–44. Scholar
  68. 68.
    Foster C, Watson A, Kaplinsky J, Kamaly N. Improved targeting of cancers with nanotherapeutics. Methods Mol Biol. 2017;1530:13–37. Scholar
  69. 69.
    Freed-Pastor W, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–86.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22(56):9030–40.PubMedGoogle Scholar
  71. 71.
    Friedrich RB, Kann B, Coradini K, Offerhaus HL, Beck RCR, Windbergs M. Skin penetration behavior of lipid-core nanocapsules for simultaneous delivery of resveratrol and curcumin. Eur J Pharm Sci. 2015;78:204–13.PubMedGoogle Scholar
  72. 72.
    Ganesan MG, Weiner ND, Flynn GL, Ho NFH. Influence of liposomal drug entrapment on percutaneous absorption. Int J Pharm. 1984;20(1–2):139–54.Google Scholar
  73. 73.
    Gatouillat G, Balasse E, Joseph-Pietras D, Morjani H, Madoulet C. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J Cell Biochem. 2010;110(4):893–902.PubMedGoogle Scholar
  74. 74.
    Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK. Nanotechnology: future of oncotherapy. Clin Cancer Res. 2015;21(14):3121–30. Scholar
  75. 75.
    Gnerre C, Catto M, Leonetti F, Weber P, Carrupt P, Altomare C, et al. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J Med Chem. 2000;43(25):4747–58.PubMedGoogle Scholar
  76. 76.
    Godin B, Touitou E. Ethosomes: new prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst. 2003;20(1):63–102.PubMedGoogle Scholar
  77. 77.
    Gonzalez-Rodriguez M, Rabasco AM. Charged liposomes as carriers to enhance the permeation through the skin. Expert Opin Drug Deliv. 2011;8(7):857–71.PubMedGoogle Scholar
  78. 78.
    Goya S, Takadate A, Tanaka T, Nakashima F. Synthesis and fluorescent properties of coumarin derivatives as analytical reagents. Yakugaku Zasshi. 1980;100(3):289–94.Google Scholar
  79. 79.
    Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851.PubMedGoogle Scholar
  80. 80.
    Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 2001;20(1):3–11.PubMedGoogle Scholar
  81. 81.
    Gugler R, Leschik M, Dengler HJ. Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol. 1975;9(23):229–34.PubMedGoogle Scholar
  82. 82.
    Gui F, Ma W, Cai S, Li X, Tan Y, Zhou C, et al. Preliminary study on molecular mechanism of curcumine anti-mouse melanoma. Pubmed. 2008;31(11):1685–9.Google Scholar
  83. 83.
    Guo F, Wang J, Ma M, Tan F, Li N. Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: characterization, in vitro and in vivo evaluation. J Mater Sci Mater Med. 2015;26(4):175.PubMedGoogle Scholar
  84. 84.
    Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.PubMedGoogle Scholar
  85. 85.
    Han T, Das DB. Potential of combined ultrasound and microneedles for enhanced transdermal drug permeation: a review. Eur J Pharm Biopharm. 2015;89(5):312–28.PubMedGoogle Scholar
  86. 86.
    Harris Z, Donovan MG, Branco GM, Limesand KH, Burd R. Quercetin as an emerging anti-melanoma agent: a four-focus area therapeutic development strategy. Front Nutr. 2016;3(48).Google Scholar
  87. 87.
    Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. 2007. Scholar
  88. 88.
    Hasty P, Christy B. p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis. 2013;3(1):22702.Google Scholar
  89. 89.
    He Y, Huang J, Sik R, Chignell C, Liu J, Waalkes M. Expression profiling of human keratinocyte response to ultraviolet A: mplications in apoptosis. J Investig Dermatol. 2004;122(2):533–43. Scholar
  90. 90.
    Heng MCY. In: Heng MCY, editor. Use of curcumin in treatment of psoriasis, inflammation, skin wounds, burns, and eczemas (WO1999042094A1 ed.). US; 1995.Google Scholar
  91. 91.
    Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420(1):25–7.PubMedGoogle Scholar
  92. 92.
    Hu C, Wang Q, Ma C, Xia Q. Non-aqueous self-double-emulsifying drug delivery system: a new approach to enhance resveratrol solubility for effective transdermal delivery. Colloids Surf A Physicochem Eng Asp. 2016;489:360–9.Google Scholar
  93. 93.
    Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 1994;54(22):5841–7.PubMedGoogle Scholar
  94. 94.
    Ijaz S, Akhtar N, Khan MS, Hameed A, Irfan M, Arshad MA, et al. Plant derived anticancer agents: a green approach towards skin cancers. Biomed Pharmacother. 2018 Jul;103:1643–51. Scholar
  95. 95.
    Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail; 2010. Scholar
  96. 96.
    Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002;22(2):197–224.PubMedGoogle Scholar
  97. 97.
    Ito A, Fujioka M, Yoshida T, Wakamatsu K, Ito S, Yamashita T, et al. 4-S-cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma. Cancer Sci. 2007;98(3):424–30.PubMedGoogle Scholar
  98. 98.
    Ito A, Matsuoka F, Honda H, Kobayashi T. Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol Immunother. 2004;53(1):26–32.PubMedGoogle Scholar
  99. 99.
    Jain P k, Joshi H. Coumarin: chemical and pharmacological profile. J Appl Pharm Sci. 2012;02(06):236–40.Google Scholar
  100. 100.
    Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. In: Jang M, editor. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes; 1997.Google Scholar
  101. 101.
    Jang S, Atkins M. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14(2):e60–9.PubMedGoogle Scholar
  102. 102.
    Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol. 2009;8(1):25–33.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Johnson ES, Kornbluth S. In: Shenolikar S, editor. Phosphatases driving mitosis: pushing the gas and lifting the brakes: Academic; 2012. Scholar
  104. 104.
    Jordan WC, Drew CR. Curcumin—a natural herb with anti-HIV activity. J Natl Med Assoc. 1996;88(6):333.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Jose A, Labala S, Ninave K, Gade S, Venuganti V. Effective skin cancer treatment by topical co-delivery of curcumin and STAT3 siRNA using cationic liposomes. AAPS PharmSciTech. 2017;19(1):166–75.PubMedGoogle Scholar
  106. 106.
    Jou PC, Tomecki KJ. Sunscreens in the United States: current status and future outlook. Adv Exp Med Biol. 2014;810:464–84.PubMedGoogle Scholar
  107. 107.
    Katiyar S, Mukhtar H. Tea in chemoprevention of cancer. Int J Oncol. 1996;8(2):221–38.PubMedGoogle Scholar
  108. 108.
    Kaur A, Webster MR, Weeraratna AT. In the wnt-er of life: Wnt signalling in melanoma and ageing. Br J Cancer. 2016;215(11):1273–1273–1279.Google Scholar
  109. 109.
    Kaushik G, Ramalingam S, Subramaniam D, Rangarajan P, Protti P, Rammamoorthy P, et al. Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells. Am J Surg. 2012;204(6):868–73.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Kenessey I, Keszthelyi M, Kramer Z, Berta J, Adam A, Dobos J e a. Inhibition of c-met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets. 2010;10(3):332–42.PubMedGoogle Scholar
  111. 111.
    Khuda-Bukhsh A, Bhattacharyya SS, Paul S, Boujedaini N. Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375. J Chin Integr Med. 2010;8(9):853.Google Scholar
  112. 112.
    Kitagawa S, Kasamaki M. Enhanced delivery of retinoic acid to skin by cationic liposomes. Chem Pharm Bull. 2006;54(2):242–4.PubMedGoogle Scholar
  113. 113.
    Kohn AD, Moon RT. Wnt and calcium signaling: β-catenin-independent pathways; 2005. Scholar
  114. 114.
    Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4(2):68–75.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Kostova I. Synthetic and natural coumarins as cytotoxic agents. Curr Med Chem AntiCancer Agents. 2005;5(1):29–46.PubMedGoogle Scholar
  116. 116.
    Kumar A, Ahuja A, Ali J, Baboota S. Conundrum and therapeutic potential of curcumin in drug deliveryrapeutic. Crit Rev Ther Drug Carrier Syst. 2010;27(4):279–312.PubMedGoogle Scholar
  117. 117.
    Kumari A, Yadav SK, Pakade YB, Singh B, Yadav SC. Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf B: Biointerfaces. 2010;80(2):184–92.PubMedGoogle Scholar
  118. 118.
    Kumari P, Muddineti OS, Rompicharla SVK, Ghanta P, A Karthik BBN, Ghosh B, et al. Cholesterol-conjugated poly(D, L-lactide)-based micelles as a nanocarrier system for effective delivery of curcumin in cancer therapy. Drug Deliv. 2017;24(1):209–23.PubMedGoogle Scholar
  119. 119.
    Kumari P, Swami MO, Nadipalli SK, Myneni S, Ghosh B, Biswas S. Curcumin delivery by poly(lactide)-based co-polymeric micelles: an in vitro anticancer study. Pharm Res. 2016;33(4):826–41.PubMedGoogle Scholar
  120. 120.
    Kurzrock R, Li L, Mehta K, Aggarawal BB. University of Texas System (Ed.), Liposomal curcumin for treatment of cancer (US7968115B2 ed.). US; 2004.Google Scholar
  121. 121.
    Kuttan R, Bhanumathy P, Nirmala K, George M. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985;29(2):197–202.PubMedGoogle Scholar
  122. 122.
    Kwatra S, Taneja G, Nasa N. Alternative routes of drug administration- transdermal, pulmonary & parenteral. Indo Global J Pharm Sci. 2012;2(4):409–26.Google Scholar
  123. 123.
    Lapteva M, Mondon K, MÃller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11(9):2989–3001.PubMedGoogle Scholar
  124. 124.
    Lee J, Jang J, Park C, Kim B, Choi Y, Choi B. Curcumin suppresses α-melanocyte stimulating hormone-stimulated melanogenesis in B16F10 cells. Int J Mol Med. 2010;26(1):101–6.PubMedGoogle Scholar
  125. 125.
    Lee W. Tumor suppressor genes—the hope. FASEB J. 1993;7(10):819.PubMedGoogle Scholar
  126. 126.
    Lee W, Shim J, Zhu B. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol. 2005;68(4):1018–30.PubMedGoogle Scholar
  127. 127.
    Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989;64(10):2024–9.PubMedGoogle Scholar
  128. 128.
    Lei M, Dong Y, Sun C, Zhang X. Resveratrol inhibits proliferation, promotes differentiation and melanogenesis in HT-144 melanoma cells through inhibition of MEK/ERK kinase pathway. Microb Pathog. 2017;111:410–3. Scholar
  129. 129.
    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323–31.PubMedGoogle Scholar
  130. 130.
    Levine A, Momand J, Finlay C. The p53 tumour suppressor gene. Nature. 1991;351(6326):453–6.PubMedGoogle Scholar
  131. 131.
    Levy DE, Darnell JE. Signalling: stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–62.PubMedGoogle Scholar
  132. 132.
    Li L, Wu L, Jiang Y, Tashiro S, Onodera S, Uchiumi F, et al. Silymarin enhanced cytotoxic effect of anti-fas agonistic antibody CH11 on A375-S2 cells. J Asian Nat Prod Res. 2007;9(7):593–602.PubMedGoogle Scholar
  133. 133.
    Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by bcl-2. EMBO J. 1999;18(21):6027–36.PubMedPubMedCentralGoogle Scholar
  134. 134.
    Lin YH, Tsai MJ, Fang YP, Fu YS, Huang YB, Wu PC. Microemulsion formulation design and evaluation for hydrophobic compound: catechin topical application. Colloids Surf B: Biointerfaces. 2018;161:121–8. Scholar
  135. 135.
    Linden K, Meyskens F. Session 7 S21. Chemoprevention of non-melanoma skin cancer: experience with a polyphenol from green tea. Eur J Cancer. 2002;38:S24.Google Scholar
  136. 136.
    Liu G, Zhang Z, Yang B, He W. Resveratrol attenuates oxidative damage and ameliorates cognitive impairment in the brain of senescence-accelerated mice; 2012. Scholar
  137. 137.
    Liu J, Chen S, Lin C, Tsai S, Liang Y. Inhibition of melanoma growth and metastasis by combination with (−)-epigallocatechin-3-gallate and dacarbazine in mice. J Cell Biochem. 2001;83(4):631–42.PubMedGoogle Scholar
  138. 138.
    Loch-Neckel G, Santos-Bubniak L, Mazzarino L, Jacques AV, Moccelin B, Santos-Silva M, et al. Orally administered chitosan-coated polycaprolactone nanoparticles containing curcumin attenuate metastatic melanoma in the lungs. J Pharm Sci. 2015;104(10):3524–34.PubMedGoogle Scholar
  139. 139.
    Losa G. Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Investig. 2003;33(9):818–23.Google Scholar
  140. 140.
    Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle P, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 33(8):665–80.PubMedGoogle Scholar
  141. 141.
    Ma Z, Molavi O, Haddadi A, Lai R, Gossage R, Lavasanifar A. Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol. 2008;63(1):27–35.PubMedGoogle Scholar
  142. 142.
    Madronich S, McKenzie R, Björn L, Caldwell M. Changes in biologically active ultraviolet radiation reaching the Earth’s surface. J Photochem Photobiol B Biol. 1998;46(1–3):5–19. Scholar
  143. 143.
    Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375–8.PubMedGoogle Scholar
  144. 144.
    Makhmalzade B, Chavoshy F. Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders. J Adv Pharm Technol Res. 2018;(1):2.Google Scholar
  145. 145.
    Malhotra U, Zaidi AH, Kosovec JE, Kasi P, Komatsu Y, Rotoloni CL, et al. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. PLoS One. 2013;8(11):e78343.PubMedPubMedCentralGoogle Scholar
  146. 146.
    Mangalathillam S, Rejinold NS, Nair A, Lakshmanan VK, Nair SV, Jayakumar R. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale. 2012;4(1):239–50. Scholar
  147. 147.
    Marin YE a, Wall BA a, Wang S a, Namkoong J a, Martino JJ a, Suh J b c, et al. Curcumin downregulates the constitutive activity of NF-κB and induces apoptosis in novel mouse melanoma cells. Melanoma Res. 2007;17(5):274–83.PubMedGoogle Scholar
  148. 148.
    Martin S, Lamb HK, Brady C, Lefkove B, Bonner MY, Thompson P, et al. Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78. Br J Cancer. 2013;109(2):433.PubMedPubMedCentralGoogle Scholar
  149. 149.
    Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. Inhibition of humanimmunodeficiency virus type-1 integrase by curcumin; 1995. Scholar
  150. 150.
    Mazzarino L, Otsuka I, Halila S, Bubniak L d S, Mazzucco S, Santos-Silva M, et al. Xyloglucan-block-poly(ϵ-caprolactone) copolymer nanoparticles coated with chitosan as biocompatible mucoadhesive drug delivery system. Macromol Biosci. 2014;14(5):709–19.PubMedGoogle Scholar
  151. 151.
    McCook JP, Persaud I, Narain NR. Topical formulations having enhanced bioavailability. 2012 US12/052,825, 2013 US13/751,769.Google Scholar
  152. 152.
    McKibbin T. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies. AJMC Peer Exchange. 2015;21:224–33.Google Scholar
  153. 153.
    Meghana PC, Hardik PH, Rajnikant SM, Sandip PR. Liposomes: as a topical drug delivery system. Int J Pharm Chem Sci. 2012;(1):1.Google Scholar
  154. 154.
    Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2):165–96.PubMedGoogle Scholar
  155. 155.
    Metodiewa D, Jaiswal AK, Cenas N, Dickancaité E, Segura-Aguilar J. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic Biol Med. 1999;26(1):107–16. Scholar
  156. 156.
    Minamimura T, Sato H, Kasaoka S, Saito T, Ishizawa S, Takemori S, et al. Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. Int J Oncol. 2000:1153–61.Google Scholar
  157. 157.
    Mirzaei H, Naseri G, Rezaee R, Mohammadi M, Banikazemi Z, Mirzaei H, et al. Curcumin: a new candidate for melanoma therapy? Int J Cancer. 2016;139(8):1683–95.PubMedGoogle Scholar
  158. 158.
    Mooney E, Ruis Peris J, O'Neill A, Sweeney E. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol. 1995;48(3):242–4. Scholar
  159. 159.
    Morris V, Toseef T, Nazumudeen F, Rivoira C, Spatafora C, Tringali C, et al. Anti-tumor properties of cis-resveratrol methylated analogues in metastatic mouse melanoma cells. Mol Cell Biochem. 2014;402(1–2):83–91.Google Scholar
  160. 160.
    Mozuraitiene J, Bielskiene K, Atkocius V, Labeikyte D. Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: targeting of notch; 2015. Scholar
  161. 161.
    Murota K, Terao J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism; 2003. Scholar
  162. 162.
    Nagula R, Wairkar S. Recent advances in topical delivery of flavonoids: a review. J Control Release. 2019;296:190–201. Scholar
  163. 163.
    Narasipura SD, Henderson LJ, Fu SW, Chen L, Kashanchi F, Al-Harthi L. Role of β-catenin and TCF/LEF family members in transcriptional activity of HIV in astrocytes. J Virol. 2012;86(4):1911–21.PubMedPubMedCentralGoogle Scholar
  164. 164.
    National Center for Biotechnology Information. PubChem Compound Database; CID=445154, (accessed 17 Feb 2019).
  165. 165.
    National Center for Biotechnology Information. PubChem Compound Database; CID=969516, (accessed 17 Feb 2019).
  166. 166.
    National Center for Biotechnology Information. PubChem Compound Database; CID=5280343, (accessed 17 Feb 2019).
  167. 167.
    Naves LB, Dhand C, Venugopal JR, Rajamani L, Ramakrishna S, Almeida L. Nanotechnology for the treatment of melanoma skin cancer. Prog Biomater. 2017;6(1):13–26.PubMedPubMedCentralGoogle Scholar
  168. 168.
    Nguyen TA, Friedman AJ. Curcumin: a novel treatment for skin-related disorders. J Drugs Dermatol. 2013;12(10):1131–7.PubMedGoogle Scholar
  169. 169.
    Nihal M, Ahmad N, Mukhtar H, Wood G. Anti-proliferative and proapoptotic effects of (?)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer. 2005;114(4):513–21.PubMedGoogle Scholar
  170. 170.
    Niles R, McFarland M, Weimer M, Redkar A, Fu Y, Meadows G. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett. 2003;190(2):157–63.PubMedGoogle Scholar
  171. 171.
    Nitta M, Azuma K, Hata K, Takahashi S, Ogiwara K, Tsuka T, et al. Systemic and local injections of lupeol inhibit tumor growth in a melanoma-bearing mouse model. Biomed Rep. 2013;1(4):641–5.PubMedPubMedCentralGoogle Scholar
  172. 172.
    Oelkrug C, Lange CM, Wenzel E, Fricke S, Hartke M, Simasi J, et al. Analysis of the tumoricidal and anti-cachectic potential of curcumin. Anticancer Res. 2014;34(9):4781–8.PubMedGoogle Scholar
  173. 173.
    Okamoto T. Safety of quercetin for clinical application (review). Int J Mol Med. 2005;16(2):275–8.PubMedGoogle Scholar
  174. 174.
    Orgaz JL, Sanz-Moreno V. Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res. 2013;26(1):39–57.PubMedGoogle Scholar
  175. 175.
    Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA, et al. CDKN2A germline mutations in individuals with cutaneous malignant melanoma; 2007. Scholar
  176. 176.
    Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J. 2005;392:249.PubMedPubMedCentralGoogle Scholar
  177. 177.
    Osmond G, Augustine C, Zipfel P, Padussis J, Tyler D. Enhancing melanoma treatment with resveratrol. J Surg Res. 2012;172(1):109–109-15.PubMedGoogle Scholar
  178. 178.
    Ossio R, Roldán-Marín R, Martínez-Said H, Adams DJ, Robles-Espinoza CD. Melanoma: a global perspective. Nat Rev Cancer. 2017:393–4. Scholar
  179. 179.
    Pal HC, Sharma S, Strickland LR, Katiyar SK, Ballestas ME, Athar M, et al. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFkappaB signaling pathways.(research article). PLoS One. 2014;9(1):e86338.PubMedPubMedCentralGoogle Scholar
  180. 180.
    Palmieri G, Colombino M, Sini MC, Ascierto PA, Lissia A, Cossu A. Duc GHT, editor. Targeted therapies in melanoma: successes and pitfalls: InTech.Google Scholar
  181. 181.
    Paluncic, J., Kovacevic, Z., Jansson, P. J., Kalinowski, D., Merlot, A. M., Huang, M. al. (2016). Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling
  182. 182.
    Panayi ND, Mendoza EE, Breshears ES, Burd R. In: Davids LM, editor. Aberrant death pathways in melanoma: InTech; 2013.Google Scholar
  183. 183.
    Pando D, Caddeo C, Manconi M, Fadda AM, Pazos C. Nanodesign of olein vesicles for the topical delivery of the antioxidant resveratrol. J Pharm Pharmacol. 2013;65(8):1158–67.PubMedGoogle Scholar
  184. 184.
    Pezzuto JM, Moon RC, Jang MS, Ouali A, Lin S, Barillas KS. In: Pharmascience Inc, editor. Pharmaceutical formulations of resveratrol and methods of use thereof (US6414037B1 ed.). US; 1998.Google Scholar
  185. 185.
    Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol. 2000;42(5, Part 1):705–26 Scholar
  186. 186.
    Ploper D, De Robertis EM. The MITF family of transcription factors: role in endolysosomal biogenesis, wnt signaling, and oncogenesis; 2015. Scholar
  187. 187.
    Propper DJ, Braybrooke JP, Levitt NC, O'Byrne K, Christodoulos K, Han C, et al. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. Br J Cancer. 2000;82(11):1759–63.PubMedPubMedCentralGoogle Scholar
  188. 188.
    Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther. 2004;3(7):641–50.PubMedGoogle Scholar
  189. 189.
    Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, et al. c-met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007;13(7):2246–53. Scholar
  190. 190.
    Qiu S, Tan S, Zhang JA, Liu A, Yuan JY, Rao GZ, et al. Apoptosis induced by curcumin and its effect on c-myc and caspase-3 expressions in human melanoma A375 cell line. 2005;25(12):1517–21.Google Scholar
  191. 191.
    Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res. 2015;32(2):389–402.PubMedGoogle Scholar
  192. 192.
    Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106(2):375–82.PubMedGoogle Scholar
  193. 193.
    Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005–11.PubMedGoogle Scholar
  194. 194.
    Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology. 1980;16(3):259–65.PubMedGoogle Scholar
  195. 195.
    Ravindranath, M. H., Ramasamy, V., Moon, S., Ruiz, C., & Muthugounder, S. Differential growth suppression of human melanoma cells by tea (camellia sinensis) epicatechins (ECG, EGC and EGCG). Evidence-Based Complementary and Alternative Medicine, (2009);6(4):523–530.Google Scholar
  196. 196.
    Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456(1):65–72. Scholar
  197. 197.
    Rigon RB, Oyafuso MH, Fujimura AT, Gonçalez ML, do Prado AH, Gremião M, et al. Nanotechnology-based drug delivery systems for melanoma antitumoral therapy: a review. Biomed Res Int. 2015;2015:841817.PubMedPubMedCentralGoogle Scholar
  198. 198.
    Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM, Ramsden CA. Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur J Cancer. 1997;33(1):135–43.PubMedGoogle Scholar
  199. 199.
    Ritchie, H., & Roser, M. (2019). Ozone layer. Retrieved from Google Scholar
  200. 200.
    Rius M, Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene. 2012;31(39):4257.PubMedGoogle Scholar
  201. 201.
    Robinson, M. J., & Cobb, M. H. (1997). Mitogen-activated protein kinase pathways Scholar
  202. 202.
    Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17(3):330–9.PubMedGoogle Scholar
  203. 203.
    Ruel-Gariépy E, Leroux J. In situ-forming hydrogels—review of temperature-sensitive systems; 2004. Scholar
  204. 204.
    Sabbatino F, Wang Y, Wang X, Ferrone S, Ferrone C. Emerging BRAF inhibitors for melanoma. Expert Opin Emerging Drugs. 2013;18(4):431–43.Google Scholar
  205. 205.
    Saha RN, Vasanthakumar S, Bende G, Snehalatha M. Nanoparticulate drug delivery systems for cancer chemotherapy. Mol Membr Biol. 2010;27(7):215–31.PubMedGoogle Scholar
  206. 206.
    Sahebkar A. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant–antioxidant mechanisms. Nat Prod Res. 2014;29(6):491–2.PubMedGoogle Scholar
  207. 207.
    Sahoo NG, Kakran M, Shaal LA, Li L, Müller RH, Pal M, et al. Preparation and characterization of quercetin nanocrystals. J Pharm Sci. 2011;100(6):2379–90.Google Scholar
  208. 208.
    Sahu S, Saraf S, Kaur C, Saraf S. Biocompatible nanoparticles for sustained topical delivery of anticancer phytoconstituent quercetin. Pak J Biol Sci. 2013;16(13):601–9.PubMedGoogle Scholar
  209. 209.
    Saitoh K, Takahashi H, Sawada N, Parsons P. Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin. J Pathol. 1994;174(3):191–9. Scholar
  210. 210.
    Sala M, Diab R, Elaissari A, Fessi H. Lipid nanocarriers as skin drug delivery systems: properties, mechanisms of skin interactions and medical applications. Int J Pharm. 2018;535(1–2):1–17. Scholar
  211. 211.
    Saleem M, Maddodi N, Abu Zaid M, Khan N, Bin Hafeez B, Asim M, et al. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res. 2008;14(7):2119.PubMedGoogle Scholar
  212. 212.
    Sanidad K, Zhu J, Wang W, Du Z, Zhang G. Effects of stable degradation products of curcumin on cancer cell proliferation and inflammation. J Agric Food Chem. 2016;64(48):9189–95.PubMedGoogle Scholar
  213. 213.
    Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri M. Epigenetic regulation in human melanoma: past and future. Epigenetics. 2015;10(2):103–21.PubMedPubMedCentralGoogle Scholar
  214. 214.
    Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, et al. Cancer development, progression, and therapy: an epigenetic overview. Basel: MDPI AG; 2013.Google Scholar
  215. 215.
    Scognamiglio I, De Stefano D, Campani V, Mayol L, Carnuccio R, Fabbrocini G, et al. Nanocarriers for topical administration of resveratrol: a comparative study. Int J Pharm. 2012;440(2).PubMedGoogle Scholar
  216. 216.
    Sharma O. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol. 1976;25(15):1811–2.PubMedGoogle Scholar
  217. 217.
    Sharma V, Kumar L, Mohanty SK, Maikhuri JP, Rajender S, Gupta G. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor—synergistic action of quercetin and curcumin. Mol Cell Endocrinol. 2016;431:12–23.PubMedGoogle Scholar
  218. 218.
    Shashanka R, Smitha B. Head and neck melanoma. ISRN Surg. 2012;2012:1–7. Scholar
  219. 219.
    Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19(19):5320–8. Scholar
  220. 220.
    Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(04):353–6.PubMedGoogle Scholar
  221. 221.
    Siddiqui IA, Bharali DJ, Nihal M, Adhami VM, Khan N, Chamcheu JC, et al. Excellent anti-proliferative and pro-apoptotic effects of (−)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo; 2014. Scholar
  222. 222.
    Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications; 2011. Scholar
  223. 223.
    Singh T, Katiyar SK. Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE(2) receptors and epithelial-to-mesenchymal transition. PLoS One. 2011;6(10):e25224.PubMedPubMedCentralGoogle Scholar
  224. 224.
    Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the akt pathway. Cancer. 2005;104(4):879–90.PubMedGoogle Scholar
  225. 225.
    Smejkalova D., Muthný, T., Nešporová, K., Hermannová, M., Achbergerová, E., Huerta-Angeles, G., et al.(2017). Hyaluronan polymeric micelles for topical drug delivery. Scholar
  226. 226.
    Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 2003;22(20):3138–51.PubMedGoogle Scholar
  227. 227.
    Steinhusen U, Badock V, Bauer A, Behrens J, Wittman-Liebold B, Dörken B, et al. Apoptosis-induced cleavage of β-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem. 2000;275(21):16345–53.PubMedGoogle Scholar
  228. 228.
    Stocker H, Andjelkovic M, Oldham S, Laffargue M, Wymann MP, Hemmings BA, et al. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science. 2002;295(5562):2088–91.PubMedGoogle Scholar
  229. 229.
    Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17(17):5001–14.PubMedPubMedCentralGoogle Scholar
  230. 230.
    Strickland L, Pal H, Elmets C, Afaq F. Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett. 2015;359(1):20–35. Scholar
  231. 231.
    Sun R, Zhao G, Xia Q. Lipid based nanocarriers with different lipid compositions for topical delivery of resveratrol: comparative analysis of characteristics and performance. J Drug Deliv Sci Technol. 2014a;24(6):591–600.Google Scholar
  232. 232.
    Sun, Y., Du, L., Liu, Y., Li, X., Li, M., Jin, Y., et al.(2014b). Transdermal delivery of the in-situ hydrogels of curcumin and its inclusion complexes of hydroxypropyl-β-cyclodextrin for melanoma treatment.
  233. 233.
    Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther. 2013;12(12):2817.PubMedGoogle Scholar
  234. 234.
    Syed D, Afaq F, Maddodi N, Johnson J, Sarfaraz S, Ahmad A, et al. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of wnt/β-catenin signaling and decreased mitf levels. J Investig Dermatol. 2011;131(6):1291–9.PubMedGoogle Scholar
  235. 235.
    Tan Q, Liu W, Guo C, Zhai G. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed. 2011;6:1621–30.Google Scholar
  236. 236.
    Tang Y, Lin R, Tsai Y, Hsu H, Yang Y, Chen C, et al. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer. Clin Cancer Res. 2012;18(16):4325.PubMedGoogle Scholar
  237. 237.
    Tarapore RS, Siddiqui IA, Saleem M, Adhami VM, Spiegelman VS, Mukhtar H. Specific targeting of wnt/β-catenin signaling in human melanoma cells by a dietary triterpene lupeol. Carcinogenesis. 2010;31(10):1844–53.PubMedPubMedCentralGoogle Scholar
  238. 238.
    Thangasamy T, Sittadjody SH, Limesand K, Burd R. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol. 2008;30(5):371–87.PubMedPubMedCentralGoogle Scholar
  239. 239.
    Thangasamy T, Sittadjody S, Lanza-Jacoby S, Wachsberger P, Limesand K, Burd R. Quercetin selectively inhibits bioreduction and enhances apoptosis in melanoma cells that overexpress tyrosinase. Nutr Cancer. 2007;59(2):258–68.PubMedGoogle Scholar
  240. 240.
    Tiwari SK, Agarwal S, Seth B, Yadav A, Nair S, Bhatnagar P, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical wnt/β-catenin pathway. ACS Nano. 2014;8(1):76.PubMedGoogle Scholar
  241. 241.
    Tortora GJ, Derrickson B. Principles of anatomy & physiology. 14th ed. Hoboken: Wiley; 2014.Google Scholar
  242. 242.
    Tyagi YK, Kumar A, Raj HG, Vohra P, Gupta G, Kumari R, et al. Synthesis of novel amino and acetyl amino-4-methylcoumarins and evaluation of their antioxidant activity; 2005. Scholar
  243. 243.
    Ugurel S, Paschen A, Becker JC. Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent. J Invest Dermatol. 2013;133(2):289–92. Scholar
  244. 244.
    Vargas, A., & Burd, R. (2010). Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutrition Reviews, 68(7), 418–428.Google Scholar
  245. 245.
    Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin; 2003. Scholar
  246. 246.
    Vogt PK, Hart JR. PI3K and STAT3: a new alliance. Cancer Discov. 2011;1(6):481–6.PubMedPubMedCentralGoogle Scholar
  247. 247.
    Volkovova K, Bilanicova D, Bartonova A, Letašiová S, Dusinska M. (2012). Associations between environmental factors and incidence of cutaneous melanoma. Review. Environ Health, 11(Suppl 1), S12.Google Scholar
  248. 248.
    Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594–604.PubMedGoogle Scholar
  249. 249.
    Wang B, Liu X, Teng Y, Yu T, Chen J, Hu Y, et al. Improving anti-melanoma effect of curcumin by biodegradable nanoparticles. Oncotarget. 2017;8(65):108624–42. Scholar
  250. 250.
    Wang M, Yu T, Zhu C, Sun H, Qiu Y, Zhu X, et al. Resveratrol triggers protective autophagy through the ceramide/Akt/mTOR pathway in melanoma B16 cells. Nutr Cancer. 2014;66(3):435–40.PubMedGoogle Scholar
  251. 251.
    Watjen W, Michels G, Steffan B, Niering P, Chovolou Y, Kampkötter A, et al. Low concentrations of flavonoids are protective in rat H4IIE cells whereas high concentrations cause DNA damage and apoptosis. J Nutr. 2005;135(3):525–31.Google Scholar
  252. 252.
    Weinberg R. Tumor suppressor genes. Science (Washington). 1991;254(5035):1138–46.Google Scholar
  253. 253.
    World Health Organization, Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation. Environmental Burden of Disease Series, N.13. 2006.Google Scholar
  254. 254.
    World Health Organization; Ultraviolet radiation (UV): skin cancers. 2019, from
  255. 255.
    Yajima I, Kumasaka M, Thang N, Goto Y, Takeda K, Yamanoshita O, et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract. 2012;354191.Google Scholar
  256. 256.
    Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer. 2009;9(6):429.PubMedPubMedCentralGoogle Scholar
  257. 257.
    Yeh M, Chen C, Hsieh D, Huang K, Chan Y, Hong P, et al. Improving anticancer efficacy of (−)-epigallocatechin-3-gallate gold nanoparticles in murine B16F10 melanoma cells. Drug Des Devel Ther. 2014;8:459–74.PubMedPubMedCentralGoogle Scholar
  258. 258.
    Yi Z, Li L, Matsushima GK, Earp HS, Wang B, Tisch R. A novel role for c-src and STAT3 in apoptotic cell-mediated MerTK-dependent immunoregulation of dendritic cells. Blood. 2009;114(15):3191.PubMedPubMedCentralGoogle Scholar
  259. 259.
    Zhang G, Miura Y, Yagasaki K. Induction of apoptosis and cell cycle arrest in cancer cells by in vivo metabolites of teas. Nutr Cancer. 2000;38(2):265–27.PubMedGoogle Scholar
  260. 260.
    Zhang Y, Li Y, Lv Y, Wang J. Effect of curcumin on the proliferation, apoptosis, migration, and invasion of human melanoma A375 cells. Genet Mol Res. 2015;14(1):1056–67.PubMedGoogle Scholar
  261. 261.
    Zhao, L., Li, Y., He, M., Song, Z., Lin, S., Yu, Z., et al. (2014). The fanconi anemia pathway sensitizes to DNA alkylating agents by inducing JNK-p53-dependent mitochondrial apoptosis in breast cancer cells.Google Scholar
  262. 262.
    Zheng N, Wang J, Yang S, Wu J. Aberrant epigenetic alteration in Eca9706 cells modulated by nanoliposomal quercetin combined with butyrate mediated via epigenetic-NF-κB signaling. Asian Pac J Cancer Prev. 2014;15(11):4539.PubMedGoogle Scholar
  263. 263.
    Zhu X, Zeng X, Zhang X, Cao W, Wang Y, Chen H, et al. The effects of quercetin-loaded PLGA-TPGS nanoparticles on ultraviolet B-induced skin damages in vivo; 2016. Scholar
  264. 264.
    Zlotogorski, A., Dayan, A., Dayan, D., Chaushu, G., Salo, T., & Vered, M. (2013). Nutraceuticals as new treatment approaches for oral cancer—I: curcumin.

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Gayathri Heenatigala Palliyage
    • 1
  • Somnath Singh
    • 1
  • Charles R. AshbyJr
    • 2
  • Amit K. Tiwari
    • 3
  • Harsh Chauhan
    • 1
    Email author
  1. 1.School of Pharmacy and Health ProfessionalsCreighton UniversityOmahaUSA
  2. 2.Department of Pharmaceutical Sciences, College of PharmacySt. John’s UniversityNew York CityUSA
  3. 3.Department of Pharmacology & Experimental Therapeutics, College of Pharmacy & Pharmaceutical SciencesFrederic and Mary Wolfe CenterToledoUSA

Personalised recommendations